New study identifies key pathway for delivering antisense cancer drugs
A study in the Journal of Cell Biology, led by Cancer Research UK Scotland Institute and University of Glasgow researchers, describes how Ionis Pharmaceuticals’ antisense oligonucleotide cET-ASOKRas enters pancreatic cancer cells via CD44, activates EPHA2, and is delivered near the nucleus. Blocking CD44 or EPHA2 reduced KRAS suppression and tumor growth; inhibiting stress granules with ISRIB enhanced effects.
How this was made
The 30-second read
Why it matters
The study maps a specific delivery pathway for an Ionis-developed ASO (cET-ASOKRas) in pancreatic cancer cells: CD44 binding triggers EPHA2-mediated endocytosis, endosomes are positioned near the nucleus, and endosomal membrane leakage enables cytoplasmic access to target mRNA. It also identifies a cellular resistance mechanism via stress granules and suggests ISRIB can enhance ASO activity.
Market read
For traders, the actionable angle is platform-level confidence in ASO delivery and a potential resistance-modulation concept, but there is no clinical or commercial milestone in the text.
What to watch
The enhancement strategy uses ISRIB in vitro; without data on tolerability, dosing, and whether similar endosomal escape can be achieved with clinically viable agents, the practical impact on future ASO performance remains uncertain.
Background
Antisense oligonucleotides (ASOs) can suppress disease by binding target mRNAs, but their intracellular delivery and routing to the nucleus and cytoplasm are not fully understood.
Ticker impact
Ionis Pharmaceuticals collaborated on the study of cET-ASOKRas, an antisense drug that reduced mutant KRAS and tumor growth in lab pancreatic cancer cells.
Near-term impact is likely limited because this is pre-publication academic mechanistic work, but it can support longer-dated confidence in ASO delivery and pipeline differentiation.
The text links Ionis to a specific ASO (cET-ASOKRas) and shows in vitro efficacy plus a defined delivery pathway (CD44, EPHA2, endosomal leakage) and a pharmacologic enhancement concept (ISRIB). However, there is no clinical outcome, trial update, or regulatory/commercial milestone.
Market effects
Mechanistic delivery insights (CD44/EPHA2 routing and stress-granule plugging) may be read across to the broader antisense delivery platform space.
No clear regional market linkage beyond UK academic institutions.
Global relevance is moderate for ASO platform investors, but the findings are pre-clinical and not tied to a specific regulatory or commercial event.
Counterpoint
Because the work is mechanistic and lab-based, it may not translate into clinical efficacy or safety, limiting any investable signal for Ionis.
Key entities
- drug_candidatecET-ASOKRas
An antisense oligonucleotide targeting mutant KRAS mRNAs; shown to reduce mutant KRAS levels and inhibit tumor growth in pancreatic cancer cells in the lab.
- cell_surface_receptorCD44
Receptor protein on the cell surface that the ASO binds to, initiating the uptake pathway.
- receptor_proteinEPHA2
Second receptor that anchors ASO-containing endosomes near the nucleus, enabling downstream cytoplasmic access.
- drugISRIB
Blocks stress granule formation in the study, enhancing cET-ASOKRas ability to suppress KRAS production.
- companyIonis Pharmaceuticals
Collaborated on the study of cET-ASOKRas, an ASO candidate targeting mutant KRAS.
